Since MAPT IVS10+16 FTD patients inherently carry the mutation already during developmental stages, there must be compensatory mechanisms such as morphogens or growth factors by supporting cell types in the brain that keep patients cognitively normal until the onset of disease. This evidence concerns the gene MAPT and frontotemporal dementia.